These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 23533713)
1. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Chazova I; Schlaich MP Int J Hypertens; 2013; 2013():541689. PubMed ID: 23533713 [TBL] [Abstract][Full Text] [Related]
2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283 [TBL] [Abstract][Full Text] [Related]
3. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. Sharma AM; Wagner T; Marsalek P J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705 [TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Kaaja R; Manhem K; Tuomilehto J Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110 [TBL] [Abstract][Full Text] [Related]
5. Use of moxonidine in elderly patients with resistant hypertension. Martin U; Hill C; O' Mahony D J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488 [TBL] [Abstract][Full Text] [Related]
6. Selective imidazoline agonist moxonidine in obese hypertensive patients. Sanjuliani AF; de Abreu VG; Francischetti EA Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870 [TBL] [Abstract][Full Text] [Related]
7. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. Rösen P; Ohly P; Gleichmann H J Hypertens Suppl; 1997 Jan; 15(1):S31-8. PubMed ID: 9050983 [TBL] [Abstract][Full Text] [Related]
8. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women. Kaaja R; Kujala S; Manhem K; Katzman P; Kibarskis A; Antikainen R; Ylihärsilä H; Erkkola R; Tuomilehto J Int J Clin Pharmacol Ther; 2007 Jul; 45(7):394-401. PubMed ID: 17725246 [TBL] [Abstract][Full Text] [Related]
9. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587 [TBL] [Abstract][Full Text] [Related]
10. [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation]. Mitrovic V; Hamel M; Miric M; Thormann J; Hamm C Z Kardiol; 2001 Dec; 90(12):953-63. PubMed ID: 11826837 [TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Prichard BN; Jäger BA; Luszick JH; Küster LJ; Verboom CN; Hughes PR; Sauermann W; Küppers HE Blood Press; 2002; 11(3):166-72. PubMed ID: 12126263 [TBL] [Abstract][Full Text] [Related]
12. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Prichard BN; Graham BR Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201 [TBL] [Abstract][Full Text] [Related]
13. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Chazova I; Almazov VA; Shlyakhto E Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753 [TBL] [Abstract][Full Text] [Related]
14. Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats. Mervaala EM; Malmberg L; Teräväinen TL; Lähteenmäki T; Karjala K; Paakkari I; Pörsti I; Mest HJ; Vapaatalo H; Karppanen H Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):107-14. PubMed ID: 9228197 [TBL] [Abstract][Full Text] [Related]
15. The use of moxonidine in the treatment of hypertension. Prichard BN; Graham BR J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986 [TBL] [Abstract][Full Text] [Related]
16. Moxonidine: a review of its use in essential hypertension. Fenton C; Keating GM; Lyseng-Williamson KA Drugs; 2006; 66(4):477-96. PubMed ID: 16597164 [TBL] [Abstract][Full Text] [Related]
17. [The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome]. Skibitsky VV; Fendrikova AV; Pyhalova NE; Sirotenko DV Kardiologiia; 2016 Sep; 56(9):32-39. PubMed ID: 28290862 [TBL] [Abstract][Full Text] [Related]
18. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. Ollivier JP; Christen MO J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Prichard BN; Owens CW; Graham BR J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737 [TBL] [Abstract][Full Text] [Related]
20. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Rupp H; Maisch B; Brilla CG Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():251-62. PubMed ID: 8827948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]